The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...
GlobalData on MSN19h
Sinaptica begins Phase II dual neurostimulation Alzheimer’s study enrolmentThe study will evaluate Sinaptica’s SinaptiStim in delivering simultaneous transcranial magnetic and alternating current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback